SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


National Association for Continuing Education
Faculty
Franck Rahaghi, MD, MHS, FCCP
Director of Advanced Lung Disease Clinic
Director, Pulmonary Hypertension Clinic
Head of Alpha-1 Foundation Clinical Resource Center
Chairman, Dept. of Pulmonary and Critical Care
Cleveland Clinic Florida
Weston, FL

Course Director and Moderator
Fernando J. Martinez, MD, MS
Executive Vice Chairman
Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medical College
New York, NY

Medical Writer
Josh Kilbridge
Kilbride Associates Healthcare Communications
San Francisco, CA

Title
: Pulmonary Arterial Hypertension and Combination Therapy: Recognizing the Role, Timing and Strategy for Advancing Care
Activity/Course #:
: NCME351
Cost:
: Free
Release/Start Date:
: Apr 01 2018
Expiration Date:
: Mar 31 2019
Topics:
: Pulmonology
Target Audience:
: Pulmonologists and Primary Care Providers
Format:
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 Hour
Credit(s):
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s)
Hardware/Software Requirements:
Program Summary
Pulmonary arterial hypertension (PAH) is a debilitating and rapidly progressive disease that was previously considered rare, but whose prevalence in the United States has been estimated at 109 and 451 per million among individuals aged <65 and >65 years respectively. About 1,000 new cases of PAH are diagnosed each year. The disease exacts an immense burden on patients and caregivers and is associated with high resource utilization and health care costs. However, despite its burden, PAH remains underdiagnosed and undertreated, with care gaps that include oversights in clinicians’ recognition of symptoms, delays in diagnosis, misdiagnosis ensuing from incomplete evaluations, delays in referral of patients to centers of expertise and initiation of therapy, and inappropriate treatment regimens.

This educational program will discuss the diagnosis and management of PAH including the role of upfront, early combination and goal-oriented therapy. The faculty will also discuss management of adverse events with PAH therapies and strategies to improve patient adherence.

This webcast was recorded live at the Conversations in Pulmonology 2018 Live Virtual Symposium and is being used with the permission of the presenters.

Learning Objectives
After completing this program participants should be able to:
  1. Discuss the diagnosis and classification of pulmonary hypertension according to the World Health Organization (WHO) clinical classification system.
  2. Outline an approach to rule out and appropriately manage chronic thromboembolic pulmonary hypertension (CTEPH), if present.
  3. Recognize the role of upfront, early combination and goal-oriented therapy for pulmonary arterial hypertension (PAH).
  4. Describe the management of adverse events with PAH therapies and strategies to improve patient adherence.

How to obtain the CME Certificate

  1. Register for the course at www.naceonline.com
  2. View the content.
  3. Complete and submit the post-test and evaluation. A minimum passing score of 70% must be earned on the post-test in order to complete the CME activity.
  4. Print your CME certificate.
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Fernando Martinez, MD, MS serves as Advisory Board/Steering Committee member to Astra Zeneca, Boehringer Ingelheim, Novartis, Peal, DSMB to Genentech, and Advisor to ProTerrix Bio.

Franck Rahaghi, MD, MHS, FCCP serves as a consultant, speaker and researcher for Actelion, Bayer, and Gilead. Dr. Rahaghi also serves as a consultant/speaker for United Therapeutics.

Gregg Sherman, MD, Activity Planning Committee, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Harvey C. Parker, Ph.D., Activity Planning Committee, has no relationships to disclose.

Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.

Sheila Lucas, CWEP, Activity Planning Committee has no relationships to disclose.

Sandy Bihlmeyer, MEd, Activity Planning Committee, has no relationship to disclose.
Commercial Support
This educational activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc.